drugset / Trial / NCT05582499

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

NCT05582499 ↗

Phase 2 Recruiting 716 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.

Timeline

Start
2022-11-01
Primary completion
2027-12-31
Completion
2029-09

Drugs

EvaluationDrugModalityDoseRoute
Subject 9MW2821 Monoclonal antibody — —
Subject Adebrelimab Monoclonal antibody — —
Subject Benmelstobart Monoclonal antibody — —
Subject Camrelizumab Monoclonal antibody — —
Subject Carboplatin Small molecule — —
Subject Catequentinib Small molecule — —
Subject Cyclophosphamide Other / unclassified — —
Subject Dalpiciclib Small molecule — —
Subject Epirubicin Small molecule — —
Subject Famitinib Small molecule — —
Subject Fluzoparib Small molecule — —
Subject Goserelin Other / unclassified — —
Subject HB1801 Unknown — —
Subject HRS-4508 Unknown — —
Subject HRS-6209 Small molecule — —
Subject IBI354 Monoclonal antibody — —
Subject Ivonescimab Monoclonal antibody — —
Subject JS207 Monoclonal antibody — —
Subject JSKN003 Monoclonal antibody — —
Subject LEM Unknown — —
Subject Letrozole Other / unclassified — —
Subject Nab-paclitaxel Small molecule — —
Subject Paclitaxel Small molecule — —
Subject Pertuzumab Monoclonal antibody — —
Subject Pyrotinib Small molecule — —
Subject Rivoceranib Small molecule — —
Subject SHR-4602 Monoclonal antibody — —
Subject SHR-A1811 Monoclonal antibody — —
Subject SHR-A1921 Monoclonal antibody — —
Subject TQB2102 Monoclonal antibody — —
Subject TQB2868 Protein / enzyme biologic — —
Subject Trastuzumab Monoclonal antibody — —